Recommended Conferences

Genetic Engineering and Gene Therapy

Paris, France

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects
 

The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers

Author(s): Karam R,Carvalho J, Bruno I, Graziadio C, Senz J, et al.

Abstract

Germline mutations in the gene encoding the tumour suppressor E-cadherin (CDH1) are the underlying genetic defect responsible for hereditary diffuse gastric cancer (HDGC). A remarkably high percentage ( approximately 80%) of CDH1 mutations in HDGC patients and carriers generate premature termination codons (PTCs). Here, we examined whether CDH1 transcripts harbouring PTCs are downregulated by nonsense-mediated decay (NMD), an RNA surveillance pathway that degrades PTC-bearing transcripts. Using an allele-specific expression (ASE) assay to differentiate between mutated and wild-type CDH1 alleles, we found that PTC-bearing CDH1 mRNAs are strongly downregulated in normal gastric tissue from several CDH1 mutation carriers. We show that NMD is responsible for this robust downregulation, as CDH1 transcripts harbouring PTCs in the KATO-III gastric tumour cell line were upregulated in response to protein synthesis inhibitors or depletion of the NMD factors UPF1 and eIF4AIII. Analysis of HDGC patients harbouring CDH1 alleles with PTCs at a wide variety of different positions indicates an association of their predicted ability to induce NMD and an earlier age of onset of gastric cancer. This suggests that NMD may be detrimental for HDGC patients and therefore NMD is a potentially useful therapeutic target for CDH1 mutation carriers.

Similar Articles

Bladder cancer biomarkers: review and update

Author(s): Ghafouri-Fard S,Nekoohesh L, Motevaseli E

Recent advances in the diagnosis and treatment of bladder cancer

Author(s): Cheung G,Sahai A, Billia M, Dasgupta P, Khan MS

Primary bladder preservation treatment for urothelial bladder cancer

Author(s): Biagioli MC, Fernandez DC, Spiess PE, Wilder RB

Prediction of muscle-invasive bladder cancer using urinary proteomics

Author(s): Schiffer E,Vlahou A, Petrolekas A, Stravodimos K, Tauber R, et al.

Making sense of cancer genomic data

Author(s): Chin L, Hahn WC, Getz G, Meyerson M

Principles and methods of integrative genomic analyses in cancer

Author(s): Kristensen VN,Lingjærde OC,Russnes HG,Vollan HK,Frigessi A, et al.

affy--analysis of Affymetrix GeneChip data at the probe level

Author(s): Gautier L, Cope L, Bolstad BM, Irizarry RA

Biomarkers for bladder cancer aggressiveness

Author(s): Frantzi M,Makridakis M, Vlahou A

Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma

Author(s): De Giorgi V, Monaco A, Worchech A, Tornesello M, Izzo F, et al.

The double bromodomain protein Brd2 promotes B cell expansion and mitogenesis

Author(s): Belkina AC, Blanton WP, Nikolajczyk BS, Denis GV

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

Author(s): Wyce A,Degenhardt Y, Bai Y, Le B, Korenchuk S, et al.

A UPF3-mediated regulatory switch that maintains RNA surveillance

Author(s): Chan WK,Bhalla AD, Le Hir H, Nguyen LS, Huang L, et al.

Targeted therapies in urothelial carcinoma

Author(s): Ghosh M,Brancato SJ, Agarwal PK, Apolo AB

Gene expression profiling and pathway analysis of superficial bladder cancer in rats

Author(s): Arum CJ,Anderssen E, Tømmerås K, Lundgren S, Chen D, et al.

Activation of RAS family genes in urothelial carcinoma

Author(s): Boulalas I,Zaravinos A, Karyotis I, Delakas D, Spandidos DA

Ras mutation cooperates with ß-catenin activation to drive bladder tumourigenesis

Author(s): Ahmad I, Patel R, Liu Y, Singh LB, Taketo MM, et al.

Ras in cancer and developmental diseases

Author(s): Fernández-Medarde A, Santos E